30 related articles for article (PubMed ID: 7658340)
1. A Systematic Degradation Kinetics Study of Dalbavancin Hydrochloride Injection Solutions.
Jakaria SM; Budil DE; Murtagh J
J Pharm Sci; 2023 Jul; 112(7):1872-1887. PubMed ID: 36780988
[TBL] [Abstract][Full Text] [Related]
2. Assay Development for Metal-Dependent Enzymes-Influence of Reaction Buffers on Activities and Kinetic Characteristics.
Forero N; Liu C; Sabbah SG; Loewen MC; Yang TC
ACS Omega; 2023 Oct; 8(43):40119-40127. PubMed ID: 37929113
[TBL] [Abstract][Full Text] [Related]
3. Effect of acetate and carbonate buffers on the photolysis of riboflavin in aqueous solution: a kinetic study.
Ahmad I; Anwar Z; Iqbal K; Ali SA; Mirza T; Khurshid A; Khurshid A; Arsalan A
AAPS PharmSciTech; 2014 Jun; 15(3):550-9. PubMed ID: 24504494
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-1: the Effects of Metal Ions and Buffers.
Jakaria SM; Budil DE; Murtagh J
Pharm Res; 2023 Oct; 40(10):2469-2478. PubMed ID: 37697173
[TBL] [Abstract][Full Text] [Related]
5. A strategy for selecting the pH of protein solutions to enhance crystallization.
Zhang CY; Wu ZQ; Yin DC; Zhou BR; Guo YZ; Lu HM; Zhou RB; Shang P
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2013 Jul; 69(Pt 7):821-6. PubMed ID: 23832217
[TBL] [Abstract][Full Text] [Related]
6. Buffer standards for the physiological pH of N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) from (278.15 to 328.15) K.
Roy RN; Roy LN; Stegner JM; Sechler SA; Jenkins AL; Krishchenko R; Henson IB
J Electroanal Chem (Lausanne); 2011 Dec; 663(1):8-13. PubMed ID: 22247703
[TBL] [Abstract][Full Text] [Related]
7. Buffer Solutions of Potassium Dihydrogen Phosphate and Sodium Succinate at 25 °C.
Paabo M; Bates RG; Robinson RA
J Res Natl Bur Stand A Phys Chem; 1963; 67A(6):573-576. PubMed ID: 31580601
[TBL] [Abstract][Full Text] [Related]
8. A kinetic oxymoron: concentration-dependent first-order rate constants for hydrolysis of ceftazidime.
Fubara JO; Notari RE
J Pharm Sci; 1998 Jan; 87(1):53-8. PubMed ID: 9452968
[TBL] [Abstract][Full Text] [Related]
9. Cyclodextrins Allow the Combination of Incompatible Vancomycin and Ceftazidime into an Ophthalmic Formulation for the Treatment of Bacterial Keratitis.
Bouattour Y; Neflot-Bissuel F; Traïkia M; Biesse-Martin AS; Frederic R; Yessaad M; Jouannet M; Wasiak M; Chennell P; Sautou V
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638878
[TBL] [Abstract][Full Text] [Related]
10. Optimization of liposomal encapsulation for ceftazidime for developing a potential eye drop formulation.
Wijesooriya C; Budai M; Budai L; Szilasi ME; Petrikovics I
J Basic Clin Pharm; 2013 Jun; 4(3):73-5. PubMed ID: 24808675
[TBL] [Abstract][Full Text] [Related]
11. How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?
Bourget P; Amin A; Dupont C; Abely M; Desmazes-Dufeu N; Dubus JC; Jouani BL; Merlette C; Nové-Josserand R; Pages J; Panzo R; Vidal F; Voge F; Hubert D
Antimicrob Agents Chemother; 2014 May; 58(5):2849-55. PubMed ID: 24614367
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: comparison of native and antibiotic-bound forms.
Sainsbury S; Bird L; Rao V; Shepherd SM; Stuart DI; Hunter WN; Owens RJ; Ren J
J Mol Biol; 2011 Jan; 405(1):173-84. PubMed ID: 20974151
[TBL] [Abstract][Full Text] [Related]
13. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Viaene E; Chanteux H; Servais H; Mingeot-Leclercq MP; Tulkens PM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2327-32. PubMed ID: 12121900
[TBL] [Abstract][Full Text] [Related]
14. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Servais H; Tulkens PM
Antimicrob Agents Chemother; 2001 Sep; 45(9):2643-7. PubMed ID: 11502544
[TBL] [Abstract][Full Text] [Related]
15. Influence of pH, temperature, and buffers on the kinetics of ceftazidime degradation in aqueous solutions.
Zhou M; Notari RE
J Pharm Sci; 1995 May; 84(5):534-8. PubMed ID: 7658340
[TBL] [Abstract][Full Text] [Related]
16. Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.
Fubara JO; Notari RE
J Pharm Sci; 1998 Dec; 87(12):1572-6. PubMed ID: 10189269
[TBL] [Abstract][Full Text] [Related]
17. Cefuroxime hydrolysis kinetics and stability predictions in aqueous solution.
Wang D; Notari RE
J Pharm Sci; 1994 Apr; 83(4):577-81. PubMed ID: 8046618
[TBL] [Abstract][Full Text] [Related]
18. The influence of pH, temperature and buffers on the degradation kinetics of cefetamet pivoxil hydrochloride in aqueous solutions.
Jelińska A; Dobrowolski L; Oszczapowicz I
J Pharm Biomed Anal; 2004 Sep; 35(5):1273-7. PubMed ID: 15336372
[TBL] [Abstract][Full Text] [Related]
19. The relationship of diastereomer hydrolysis kinetics to shelf-life predictions for cefuroxime axetil.
Nguyen NA
Pharm Res; 1991 Jul; 8(7):893-8. PubMed ID: 1924141
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
